Featured Resources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
modalities
Peptides and Macrocycles
We help you turn complex peptide ideas into powerful therapies combining deep scientific expertise with collaborative problem-solving to move your program forward, faster.
supporting your research
Peptides are one of the fastest-growing therapeutic classes, bridging the space between small molecules and biologics.
Their defined amino acid sequences offer high target specificity, strong safety profiles, and the flexibility to tackle previously unreachable biological pathways. Many approved drugs already use peptide scaffolds, and their modular nature makes them key players in the rise of personalized and precision medicine.
Breakthroughs in synthetic chemistry, conjugation methods, and computational design are accelerating peptide discovery, turning complex molecular structures into next-generation therapies with the power to reshape standards of care.
At Sygnature Discovery, we bring together chemistry, bioscience, computational design, and in vivo pharmacology to help partners turn complex peptide ideas into real-world medicines. Our end-to-end services span peptide design, advanced analytics, synthetic chemistry, and discovery biology, driving progress where others hit roadblocks.
How We Can Help
Peptide Drug Discovery Expertise
• Design and integration of both canonical and non-canonical amino acids
• Backbone modifications including N-methylation and peptide derivatives to expand chemical diversity
• Automated synthesis of peptides ranging from 20 to 100 amino acids, available as singletons or in 96-well plate format
• Macrocyclization using diverse ring closure chemistries (click reactions, metathesis, disulfide formation, and more)
• Computational tools to guide optimization and structure–activity relationships
• Experience with conjugated formats such as peptide–drug conjugates and hybrid modalities
• Broad chemical expertise including carbohydrates, nucleosides, macrocycles, linkers, and lipid chemistries
Integrated Discovery Support
• Plasma stability assays in mouse and human models
• in vivo dosing and functional assays
• Seamless integration of medicinal chemistry, bioscience, and DMPK
• Proof-of-concept in vivo studies to support clinical translation
Enabling Technologies
• State-of-the-art platforms: ELNs, LCMS/UPLC, high-field NMR, automated purification, and liquid handling
• Streamlined procurement systems for cost-effective and reliable supply
Advance Analytical Services
• Protein mass spectrometry: intact mass, native MS, and peptide mapping
• Electrophysiology platforms for ion channel interaction assays
• Transporter assays including hPepT1 for membrane transport and uptake
• GPCR assays with beta-arrestin and cAMP readouts
Why Choose Sygnature Discovery?
At Sygnature Discovery, we combine deep scientific expertise, cutting-edge technologies, and collaborative thinking to:
• Unlock the potential of peptides, conjugates, and peptidomimetics
• Navigate the complexity of peptide design and development
• Deliver innovative therapeutic candidates that make a meaningful impact
By going beyond standard synthesis, our expert teams open new possibilities in peptide therapeutics, transforming complexity into opportunity and shaping the future of peptide-based medicine.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Sitryx: Empowering New Ideas
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Corcept Therapeutics: Integrated Drug Discovery Collaboration
Corcept Therapeutics, located in Menlo Park, CA, is a leader in the discovery and development of drugs that regulate the effects of cortisol.
CellCentric Lead Optimisation Campaign – CCS1477
CellCentric are developing new treatments for cancer based on their understanding of epigenetics.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates
UK-based small molecule drug discovery company
Focus on identifying novel treatments of inflammatory respiratory diseases, such as COPD
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Synthetic Chemistry
Creative, scalable synthetic chemistry solutions using modern methodologies and advanced tools, transforming complex challenges into efficient, high-quality outcomes.
Separation Sciences
Integrated purification and analytical solutions using advanced SFC and HPLC delivering high-purity compounds from milligram to kilogram scale with confidence.
Chemistry
Global chemistry expertise and tailored strategies combining medicinal, synthetic, and process capabilities advancing candidate-quality molecules with transparent collaboration.